Technology Listings

PET Tracer for Parkinson’s Disease Diagnostic


Small molecule PET tracer for Lewy bodies in the brain for diagnosing Parkinson’s Disease or other Lewy body related diseases.

Key Benefits
  • PET tracer to enable quantification of α-Syn.
  • Improves diagnosis of Parkinson’s disease.
  • Allows for earlier treatment.
Market Summary

Parkinson’s disease is a neurodegenerative disorder that causes movement issues such as tremors, slowness, limb rigidity and balance problems. In the brains of patients with Parkinson’s, there are abnormal protein deposits called Lewy bodies that consist of α-Syn. There are currently no blood or laboratory tests consistent in effectively diagnosing the disease. Current diagnosis relies on medical history, a neurological examination, and ruling out other diseases. An imaging tracer that quantifies α-Syn aggregation in vivo, would greatly improve clinical diagnosis.

Technical Summary

Scientists at Emory have found a PET tracer that enables the quantification of α-Syn aggregates in Lewy bodies and Lewy neuritis. The PET tracers have been evaluated against Tau and A-beta and they show high selectivity for α-Syn. These tracers may improve diagnosis of Parkinson’s disease as well as enable earlier treatment.

Developmental Stage

In vivo imaging studies in mice are currently underway.

Patent Information
App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
PCT PCT PCT/US2019/032592   5/16/2019   11/16/2020 Pending
Tech ID: 18035
Published: 8/26/2019

Sarah Wilkening
Licensing Associate
Emory University
(404) 727-1969

Keqiang Ye

Small Molecule